AU2015286049B2 - Aromatic heterocyclic derivatives and pharmaceutical applications thereof - Google Patents

Aromatic heterocyclic derivatives and pharmaceutical applications thereof Download PDF

Info

Publication number
AU2015286049B2
AU2015286049B2 AU2015286049A AU2015286049A AU2015286049B2 AU 2015286049 B2 AU2015286049 B2 AU 2015286049B2 AU 2015286049 A AU2015286049 A AU 2015286049A AU 2015286049 A AU2015286049 A AU 2015286049A AU 2015286049 B2 AU2015286049 B2 AU 2015286049B2
Authority
AU
Australia
Prior art keywords
mmol
compound
piperazin
indole
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015286049A
Other languages
English (en)
Other versions
AU2015286049A1 (en
Inventor
Kangzhi CHEN
Li Gao
Chuanfei JIN
Runzhi LIU
Ji Zhang
Yingjun Zhang
Wenhe ZHONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of AU2015286049A1 publication Critical patent/AU2015286049A1/en
Application granted granted Critical
Publication of AU2015286049B2 publication Critical patent/AU2015286049B2/en
Assigned to NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED reassignment NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED Request for Assignment Assignors: SUNSHINE LAKE PHARMA CO., LTD.
Assigned to SUNSHINE LAKE PHARMA CO., LTD. reassignment SUNSHINE LAKE PHARMA CO., LTD. Request for Assignment Assignors: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015286049A 2014-07-08 2015-07-08 Aromatic heterocyclic derivatives and pharmaceutical applications thereof Active AU2015286049B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410324179.6 2014-07-08
CN201410324179 2014-07-08
PCT/CN2015/083605 WO2016004882A1 (en) 2014-07-08 2015-07-08 Aromatic heterocyclic derivatives and pharmaceutical applications thereof

Publications (2)

Publication Number Publication Date
AU2015286049A1 AU2015286049A1 (en) 2016-12-15
AU2015286049B2 true AU2015286049B2 (en) 2018-03-01

Family

ID=55063598

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015286049A Active AU2015286049B2 (en) 2014-07-08 2015-07-08 Aromatic heterocyclic derivatives and pharmaceutical applications thereof

Country Status (8)

Country Link
US (1) US9974785B2 (https=)
EP (1) EP3166924B1 (https=)
JP (1) JP6515175B2 (https=)
CN (1) CN105541693B (https=)
AU (1) AU2015286049B2 (https=)
CA (1) CA2953004C (https=)
SG (1) SG11201610407QA (https=)
WO (1) WO2016004882A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232362B (zh) * 2017-07-10 2022-12-27 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
WO2020117075A1 (en) * 2018-12-06 2020-06-11 Jagiellonian University Arylsulfonamides of 2-arylpyrrole-3-carboxamides for the treatment of cns disorders
CN111233736B (zh) * 2020-03-16 2021-07-16 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN111362858B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN111362859B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN111233737B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN117024326A (zh) * 2023-07-26 2023-11-10 平顶山学院 5位氨基取代吲哚化合物及其制备方法和在抗乙酰胆碱酯酶药物中的应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085892A1 (en) * 2001-04-20 2002-10-31 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2002102774A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2008003703A1 (en) * 2006-07-03 2008-01-10 Biovitrum Ab (Publ) Indoles as 5-ht6 modulators
WO2008084491A1 (en) * 2007-01-08 2008-07-17 Suven Life Sciences Limited 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands
WO2008084492A1 (en) * 2007-01-08 2008-07-17 Suven Life Sciences Limited 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
WO2008101247A2 (en) * 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
WO2008147812A2 (en) * 2007-05-24 2008-12-04 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-ht6 receptor affinity
WO2009034581A1 (en) * 2007-09-11 2009-03-19 Suven Life Sciences Limited Substituted indolyl compounds and their use as 5-ht6 ligands
WO2011016528A1 (ja) * 2009-08-07 2011-02-10 中外製薬株式会社 アミノピラゾール誘導体
WO2011088836A1 (en) * 2010-01-25 2011-07-28 H. Lundbeck A/S NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
ATE375990T1 (de) 1999-04-21 2007-11-15 Nps Allelix Corp Piperidin-indol derivate mit 5-ht6 affinität
WO2001012629A1 (en) 1999-08-12 2001-02-22 Nps Allelix Corp. Azaindoles having serotonin receptor affinity
US6897215B1 (en) 1999-11-05 2005-05-24 Nps Allelix Corp. Compounds having 5-HT6 receptor antagonist activity
AU2001296193B2 (en) 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP2298738B1 (en) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2002220715A1 (en) 2000-11-24 2002-06-03 Smithkline Beecham Plc Indolsulfonyl compounds useful in the treatment of cns disorders
EA200300716A1 (ru) 2000-12-22 2003-12-25 Уайт Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
MXPA03005432A (es) 2000-12-22 2003-09-10 Wyeth Corp Compuestos de heterociclilindazol y -azaindazol como ligandos de 5-hidroxitriptamina-6.
US7271180B2 (en) 2001-01-23 2007-09-18 Wyeth 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
ATE340795T1 (de) 2001-01-30 2006-10-15 Lilly Co Eli Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
WO2002085853A2 (en) 2001-04-20 2002-10-31 Wyeth Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
EP1401813B1 (en) 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
WO2003013510A1 (en) 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
GB0202679D0 (en) 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
DE60322186D1 (de) 2002-02-12 2008-08-28 Organon Nv 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem
JP2005527542A (ja) 2002-03-27 2005-09-15 グラクソ　グループ　リミテッド キノリンおよびアザインドール誘導体およびその５−ｈｔ６リガンドとしての使用
PL374401A1 (en) 2002-06-05 2005-10-17 F.Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
MXPA05002696A (es) 2002-09-17 2005-05-05 Hoffmann La Roche Indoles 2,7-sustituidos y su uso como moduladores de 5-hidroxitriptamina 6 (5-ht6).
ES2311721T3 (es) 2002-09-17 2009-02-16 F. Hoffmann-La Roche Ag Indoles sustituidos en posicion 2,4 y su empleo como moduladores de 5-ht6.
PL376479A1 (en) * 2002-10-18 2005-12-27 F.Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
BRPI0315959C1 (pt) 2002-11-28 2021-05-25 Suven Life Sciences Ltd composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto
KR100755580B1 (ko) 2002-12-03 2007-09-06 에프. 호프만-라 로슈 아게 Ｃｎｓ-장애의 치료를 위한 5-ｈｔ6-수용체 리간드로서의아미노알콕시인돌
EP1592690A1 (en) 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
KR20050101551A (ko) 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
WO2004108671A1 (en) 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
ES2222828B1 (es) 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
GB0320320D0 (en) 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
SE0302760D0 (sv) 2003-10-20 2003-10-20 Biovitrum Ab New compounds
TW200524864A (en) 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
ES2291984T3 (es) 2003-12-09 2008-03-01 F. Hoffmann-La Roche Ag Derivados de benzoxazina y su empleo.
WO2005066157A1 (en) 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US7378415B2 (en) 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
AU2005291541B2 (en) * 2004-09-30 2011-03-10 F. Hoffmann-La Roche Ag Benzoxazine and quinoxaline derivatives and uses
GB0422263D0 (en) 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
EP1676841A1 (en) 2004-12-30 2006-07-05 Esteve Laboratorios Dr. Esteve S.A. Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
BRPI0613430A2 (pt) 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica
EA013875B1 (ru) 2005-08-12 2010-08-30 Сувен Лайф Сайенсиз Лимитед Аминоарильные сульфонамидные производные как функциональные 5-нтлиганды
WO2007020653A1 (en) 2005-08-12 2007-02-22 Suven Life Sciences Limited Thioether derivatives as functional 5-ht6 ligands
WO2007084841A2 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
CA2637531A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
WO2007138611A1 (en) 2006-05-30 2007-12-06 Suven Life Sciences Limited 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands
PE20080707A1 (es) 2006-06-01 2008-05-22 Wyeth Corp Derivados de benzoxazol y benzotiazol como ligandos de 5-hidroxitriptamina-6
WO2008055808A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
EP1947085A1 (en) 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
JP2010517976A (ja) 2007-02-06 2010-05-27 ノバルティス アーゲー Ｃｃｒ９活性の阻害剤としての１−ベンゼンスルホニル−１ｈ−インドール誘導体
US7557108B2 (en) 2007-02-07 2009-07-07 Hoffmann-La Roche Inc. (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones
US8507469B2 (en) 2007-03-23 2013-08-13 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
BRPI0809873A2 (pt) 2007-05-03 2018-11-13 Suven Life Sciences Ltd "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
EP2158195A1 (en) 2007-05-15 2010-03-03 Wyeth LLC 5- (aminoazacyclyl) -3-sulfonyl-lh- indazoles as 5-hydroxytryptamine- 6 ligands for the treatment of cns disorders
EP2016943B1 (en) 2007-07-19 2011-02-23 Laboratorios del Dr. Esteve S.A. Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
AU2008286760A1 (en) 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-HT6 receptor affinity
US8453188B2 (en) 2008-01-22 2013-05-28 Avaya Inc. Open cable application platform set-top box (STB) personal profiles and communications applications
RU2378278C2 (ru) 2008-01-24 2010-01-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
RU2384581C2 (ru) 2008-05-07 2010-03-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛ-ТЕТРАГИДРО-ПИРАЗОЛО[1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2009155399A1 (en) 2008-06-20 2009-12-23 Wyeth 1-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligands
US20100016297A1 (en) 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056491A1 (en) 2008-08-29 2010-03-04 Memory Pharmaceuticals Corporation 4'-amino cyclic compounds having 5-ht6 receptor affinity
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
KR20110069148A (ko) 2008-10-06 2011-06-22 알라 캠, 엘엘씨 치환된 3-아릴설포닐-피라졸로［1,5-ａ］피리미딘, 세로토닌 5-ＨＴ6 수용체의 길항제, 물질의 제조방법 및 이의 용도
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
US8153680B2 (en) 2009-08-25 2012-04-10 The Ohio State University Research Foundation Alkyl indole-3-carbinol-derived antitumor agents
CA2786072C (en) 2010-01-05 2014-10-28 Suven Life Sciences Limited Sulfone compounds as 5-ht6 receptor ligands
KR101269594B1 (ko) 2010-12-07 2013-06-05 주식회사 바이오리더스 Ｌ형 폴리감마글루탐산을 생산하는 신규 미생물 바실러스 메가테리움 토하 및 이로부터 생산된 ｌ형 폴리감마글루탐산
US10266490B2 (en) 2012-03-16 2019-04-23 Georgetown University Radioprotector compounds
RU2500672C1 (ru) 2012-10-25 2013-12-10 Андрей Александрович Иващенко (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
CN104276993B (zh) 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
DK3027613T3 (en) 2013-07-25 2018-06-25 Univ Jagiellonski Pyrroloquinoline derivatives as 5-HT6 antagonists, preparation and use thereof
CN104557726B (zh) 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085892A1 (en) * 2001-04-20 2002-10-31 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2002102774A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2008003703A1 (en) * 2006-07-03 2008-01-10 Biovitrum Ab (Publ) Indoles as 5-ht6 modulators
WO2008084491A1 (en) * 2007-01-08 2008-07-17 Suven Life Sciences Limited 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands
WO2008084492A1 (en) * 2007-01-08 2008-07-17 Suven Life Sciences Limited 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
WO2008101247A2 (en) * 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
WO2008147812A2 (en) * 2007-05-24 2008-12-04 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-ht6 receptor affinity
WO2009034581A1 (en) * 2007-09-11 2009-03-19 Suven Life Sciences Limited Substituted indolyl compounds and their use as 5-ht6 ligands
WO2011016528A1 (ja) * 2009-08-07 2011-02-10 中外製薬株式会社 アミノピラゾール誘導体
WO2011088836A1 (en) * 2010-01-25 2011-07-28 H. Lundbeck A/S NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS

Also Published As

Publication number Publication date
US9974785B2 (en) 2018-05-22
SG11201610407QA (en) 2017-01-27
CA2953004C (en) 2023-02-21
JP6515175B2 (ja) 2019-05-15
AU2015286049A1 (en) 2016-12-15
CA2953004A1 (en) 2016-01-14
US20170096392A1 (en) 2017-04-06
EP3166924B1 (en) 2019-02-20
WO2016004882A1 (en) 2016-01-14
EP3166924A1 (en) 2017-05-17
CN105541693A (zh) 2016-05-04
JP2017519798A (ja) 2017-07-20
CN105541693B (zh) 2018-10-16
HK1232222A1 (en) 2018-01-05
EP3166924A4 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
AU2015286049B2 (en) Aromatic heterocyclic derivatives and pharmaceutical applications thereof
EP3083589B1 (en) Substituted piperazine compounds and methods of use thereof
CN107266455B (zh) 三唑并吡嗪
AU2016360245A1 (en) Octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof
US9663498B2 (en) Aromatic heterocyclic compounds and their application in pharmaceuticals
CN104725249A (zh) 苄胺类衍生物及其在药物上的应用
EP3027607B1 (en) Substituted heteroaryl compounds and methods of use thereof
US9840482B2 (en) Sulfonamide derivatives and pharmaceutical applications thereof
CN105367472B (zh) 吲哚啉类衍生物及其在药物上的应用
CN106045967B (zh) 取代杂环化合物及其在药物上的应用
CN104496987B (zh) 取代杂环类化合物及其在药物上的应用
CN106045966B (zh) 取代杂环化合物及其在药物上的应用
HK1232222B (en) Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CN104529866A (zh) 吲哚类衍生物及其在药物上的应用
CN105367473B (zh) 吲哚啉类衍生物及其在药物上的应用
CN110117264B (zh) 苯基砜衍生物及其在药物上的应用
CN104529865B (zh) 苄胺类衍生物及其在药物上的应用
CA3000063C (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CA3000063A1 (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
HK1210169B (en) Triazolopyrazine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY

Free format text: FORMER OWNER(S): SUNSHINE LAKE PHARMA CO., LTD.

PC Assignment registered

Owner name: SUNSHINE LAKE PHARMA CO., LTD.

Free format text: FORMER OWNER(S): NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED